Program
BRAF V600E Inhibitor HLX208
Also written as “HLX208”, “[14C]HLX208” and “HLX 208”.
In Fosun Pharma’s pipeline, BRAF V600E
. Its studies are mostly in Thyroid Carcinoma, Anaplastic · Colorectal Neoplasms · Histiocytosis, Langerhans-Cell · Carcinoma, Non-Small-Cell Lung · Brain Neoplasms, led by Fosun Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 127 open or running | phase 2since Jul 27, 2021 | Jun 9, 2021 | none ahead |
- Named in Fosun Pharma’s own pipeline as
HLX208 (BRAF V600E)
, phase 2, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2021First study: phase 1 study in Solid TumorFirst studyNCT04965220 · 220 planned · China
- Jul 27, 2021Phase 2 study in CRCNCT04984369 · 50 enrolled · China
- Sep 9, 20213 phase 2 studiesNCT05065398, NCT05092802, NCT05092815
- Oct 20, 20212 phase 2 studiesNCT05102292, NCT05114603
- Nov 9, 2021Phase 2 study in Colorectal NeoplasmsNCT05127759 · 25 enrolled · China
- Sep 2, 2022Phase 2 study in Solid TumorNCT05528406 · 30 planned
- Nov 15, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05641493 · 49 planned · China
- Apr 24, 2023Phase 1 study in Mass Balance Study in Healthy SubjectsNCT05841940 · 6 enrolled · China
- May 24, 2023Phase 1 study in NSCLCNCT05902728 · 20 enrolled · China
TargetBeta
“BRAF V600E”the company's pipeline, read by Claude · source
Other programs on BRAF
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
| tovorafenibrule | day-one-biopharmaceuticals-inc | phase 3 | 8 |
| belvarafenibrule | Hanmi Pharmaceutical | phase 2 | 6 |
| claturafenib | Pfizer | phase 1 | 2 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05902728NSCLC · China | 1 | Completed | Dec 19, 2023 | 20 |
| NCT05841940Mass Balance Study in Healthy Subjects · China | 1 | Completed | Jul 15, 2023 | 6 |
| NCT05641493Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Mar 4, 2025 | 49 |
| NCT05528406Solid Tumor | 2 | Not yet recruiting | Oct 30, 2024 | 30 |
| NCT05127759Colorectal Neoplasms · China | 2 | Active, not recruiting | Jan 30, 2024 | 25 |
| NCT05114603Advanced Melanoma · China | 2 | UNKNOWN | Aug 30, 2023 | 30 |
| NCT05102292Thyroid Carcinoma, Anaplastic · China | 2 | Active, not recruiting | Jun 30, 2024 | 25 |
| NCT05092815Histiocytosis, Langerhans-Cell · China | 2 | Active, not recruiting | Jun 30, 2024 | 25 |
| NCT05092802Brain Neoplasms · China | 2 | UNKNOWN | May 30, 2023 | 40 |
| NCT05065398NSCLC · China | 2 | UNKNOWN | Jun 30, 2023 | 20 |
| NCT04984369CRC · China | 2 | Active, not recruiting | Jun 15, 2024 | 50 |
| NCT04965220Solid Tumor · China | 1 | Recruiting | Jun 30, 2024 | 220 |
How it is read
Names in the registry
- “HLX208”, 12 entries
- “[14C]HLX208”, 1 entry
- “HLX 208”, 1 entry
- “HLX208+HLX10”, 1 entry
Conditions, from the studies’ own filings
- Thyroid Carcinoma, Anaplastic, 1 study
- Colorectal Neoplasms, 1 study
- Histiocytosis, Langerhans-Cell, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Brain Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.